Safety of GLP-1’s

  • This topic has 5 replies, 5 voices, and was last updated 1 year ago by Roshni John.
Viewing 5 reply threads
  • Author
    Posts
    • #31206
      Shauna Prouten
      Participant

      Diabetes Education

      What do we know about long term safety of using GLP-1’s?

    • #31245
      Linda Mireku
      Participant

      Diabetes Education

      I think long term effects will dependent on the individual – such as those with pancreatic and thyroid issues.

    • #31332
      Ana Neves
      Participant

      Diabetes Education

      Agreed.

    • #31372
      Janet Wilpstra
      Participant

      Diabetes Education

      Google answer:
      Data from DURATION-1 demonstrated that continuous HbA1c reductions and weight loss were observed for the patients continuing on the treatment, with no unexpected adverse events. Taken together, these data support GLP-1RAs as a long-term noninsulin treatment option after the failure of oral therapy.

      We are responsible to monitor for changes in client status…regular DEP visits and bloodwork

    • #31373
      Janet Wilpstra
      Participant

      Diabetes Education

      Google answer:
      Data from DURATION-1 demonstrated that continuous HbA1c reductions and weight loss were observed for the patients continuing on the treatment, with no unexpected adverse events. Taken together, these data support GLP-1RAs as a long-term noninsulin treatment option after the failure of oral therapy.

      We are responsible to monitor for changes in client status…regular DEP visits and bloodwork as well as collaboration with PCP

    • #31423
      Roshni John
      Participant

      Diabetes Education

      Mostly considered safe. GI adverse reactions are common but can be minimized with gradual dose titration and eating behavior modification. Ongoing monitoring and evaluation followed by dose adjustments with the patient’s consent based on the patient’s health status would be the clinician’s responsibility.
      They are contraindicated in patients with a family history of medullary thyroid carcinoma and/or multiple endocrine neoplasia syndrome type 2, pancreatitis, renal impairment,

Viewing 5 reply threads
  • You must be logged in to reply to this topic.
Scroll to Top

The
Essentials

Welcome,

Programs

Diabetes Canada

The Essentials